{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:28:58Z","timestamp":1747913338921,"version":"3.37.3"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Roche Hellas SA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Rheumatoid arthritis (RA) is a systemic, inflammatory disease affecting multiple organs and causing physical disability over time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The primary objective was to evaluate treatment persistence to subcutaneous tocilizumab (TCZ-SC). Additionally, treatment effects on persistence and their associations with clinical and patient-reported outcomes were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We performed a multicenter, non-interventional, 52-week observational study on 222 patients with moderate or severe RA. Clinical outcomes were evaluated by using disease activity score for 28 joints (DAS28) and European League Against Rheumatism (EULAR) response, and patients\u2019 perceptions were evaluated by using Health Assessment Questionnaire (HAQ), Visual Analog Scale (VAS) for pain, and patient global assessment (PtGA) of disease activity. Safety was assessed throughout the study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of the overall cohort was 62.2\u2009\u00b1\u200912.3\u00a0years, and 83.8% were females. Persistence to TCZ-SC was 89.6% at week 24 and 85.1% at week 52 in the overall cohort with slightly increased persistence in the combination group. At week 52, changes from the baseline were\u2009\u2212\u20092.68 in DAS28,\u2009\u2212\u20090.76 in HAQ,\u2009\u2212\u200943.21 in VAS pain, and\u2009\u2212\u200941.66 in PtGA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001 for all). Moderate and good EULAR response was achieved in 83.2% of patients. Non-serious and serious adverse events occurred in 18.5% and 3.2% of the participants, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The current study confirms the favorable safety and effectiveness of TCZ-SC as well as its acceptability by RA patients in Greece, with sustained high persistence rates up to 52\u00a0weeks. TCZ-SC offers a sustainable treatment response in RA.<jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>Based upon clinical and patient-reported outcomes, TCZ-SC is a highly effective and safe treatment modality in patients with moderate-to-severe RA.<\/jats:italic>\u2022 <jats:italic>Persistence to TCZ-SC was high throughout the study, both as monotherapy and in combination with csDMARDs.<\/jats:italic>\u2022 <jats:italic>TCZ-SC is effective both as monotherapy and when used in combination with other csDMARDs regardless of the line of treatment.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-024-06916-5","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T22:01:51Z","timestamp":1710280911000},"page":"1469-1478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Persistence on subcutaneous tocilizumab as monotherapy or in combination with synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients in Greece (EMBRACE study): a multicenter, post-marketing, non-interventional, observational trial"],"prefix":"10.1007","volume":"43","author":[{"given":"Panagiotis","family":"Athanassiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pelagia","family":"Katsimbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Bounas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u03bfusana","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodosios","family":"Sarikoudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8230-6626","authenticated-orcid":false,"given":"Victoria","family":"Syrigou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Boumpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"EMBRACE Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kallitsakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Kampakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kandyli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasios","family":"Kotrotsios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eftychia-Maria","family":"Koukli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Ksirogiannis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aristeidis","family":"Lagoudakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clio","family":"Mavragani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra","family":"Mavridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavlos","family":"Merantzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodoros","family":"Natskos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios E.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Psaltis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Tsiakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Zakalka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Ziogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"issue":"10055","key":"6916_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023\u20132038","journal-title":"Lancet"},{"issue":"1","key":"6916_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA et al (2023) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis 82(1):3\u201318","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6916_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.ahj.2013.07.010","volume":"166","author":"CS Crowson","year":"2013","unstructured":"Crowson CS, Liao KP, Davis JM 3rd et al (2013) Rheumatoid arthritis and cardiovascular disease. Am Heart J 166(4):622-628.e1","journal-title":"Am Heart J"},{"issue":"135","key":"6916_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1183\/09059180.00008014","volume":"24","author":"S Megan","year":"2015","unstructured":"Megan S, Bridget FC, Lawrence AH et al (2015) Rheumatoid arthritis-associated lung disease. Eur Respir Rev 24(135):1","journal-title":"Eur Respir Rev"},{"issue":"8840","key":"6916_CR5","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/0140-6736(93)92628-7","volume":"341","author":"P Brooks","year":"1993","unstructured":"Brooks P (1993) Clinical management of rheumatoid arthritis. The Lancet 341(8840):286\u2013290","journal-title":"The Lancet"},{"issue":"5","key":"6916_CR6","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/ije\/31.5.1079-a","volume":"31","author":"P Dieppe","year":"2002","unstructured":"Dieppe P (2002) Epidemiology of the rheumatic diseases second edition. AJ Silman, MC Hochberg (eds). Oxford: Oxford University Press, 2001, pp. 377, \u00a395.00. ISBN: 0192631497. Int J Epidemiol 31(5):1079\u20131080","journal-title":"Int J Epidemiol"},{"issue":"22","key":"6916_CR7","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586\u20131593","journal-title":"N Engl J Med"},{"issue":"9","key":"6916_CR8","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552\u20131563","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"6916_CR9","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/ar2666","volume":"11","author":"A Rubbert-Roth","year":"2009","unstructured":"Rubbert-Roth A, Finckh A (2009) Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 11(Suppl 1):S1","journal-title":"Arthritis Res Ther"},{"key":"6916_CR10","doi-asserted-by":"publisher","first-page":"d340","DOI":"10.2741\/A136","volume":"1","author":"ET Keller","year":"1996","unstructured":"Keller ET, Wanagat J, Ershler WB (1996) Molecular and cellular biology of interleukin-6 and its receptor. Front Biosci 1:d340-57","journal-title":"Front Biosci"},{"key":"6916_CR11","first-page":"153","volume":"51","author":"T Hirano","year":"1992","unstructured":"Hirano T (1992) The biology of interleukin-6. Chem Immunol 51:153\u201380","journal-title":"Chem Immunol"},{"issue":"5","key":"6916_CR12","doi-asserted-by":"publisher","first-page":"E957","DOI":"10.1152\/ajpendo.2001.281.5.E957","volume":"281","author":"S Metzger","year":"2001","unstructured":"Metzger S, Hassin T, Barash V et al (2001) Reduced body fat and increased hepatic lipid synthesis in mice bearing interleukin-6-secreting tumor. Am J Physiol Endocrinol Metab 281(5):E957\u2013E965","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"24","key":"6916_CR13","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","volume":"90","author":"T Tamura","year":"1993","unstructured":"Tamura T, Udagawa N, Takahashi N et al (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 90(24):11924\u201311928","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"6916_CR14","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1172\/JCI19974","volume":"112","author":"R Taub","year":"2003","unstructured":"Taub R (2003) Hepatoprotection via the IL-6\/Stat3 pathway. J Clin Invest 112(7):978\u2013980","journal-title":"J Clin Invest"},{"issue":"6","key":"6916_CR15","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/art.1780310614","volume":"31","author":"FA Houssiau","year":"1988","unstructured":"Houssiau FA, Devogelaer JP, Van Damme J et al (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31(6):784\u2013788","journal-title":"Arthritis Rheum"},{"issue":"6","key":"6916_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","volume":"16","author":"EH Choy","year":"2020","unstructured":"Choy EH, De Benedetti F, Takeuchi T et al (2020) Translating IL-6 biology into effective treatments. Nat Rev Rheumatol 16(6):335\u2013345","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"6916_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6916_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/17425247.2019.1618828","volume":"16","author":"A Ogata","year":"2019","unstructured":"Ogata A, Kato Y, Higa S et al (2019) Subcutaneous tocilizumab: recent advances for the treatment of rheumatoid arthritis. Expert Opin Drug Deliv 16(6):639\u2013648","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"6916_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"GR Burmester","year":"2014","unstructured":"Burmester GR, Rubbert-Roth A, Cantagrel A et al (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73(1):69\u201374","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"6916_CR20","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1136\/ard.2004.031476","volume":"64","author":"A Zink","year":"2005","unstructured":"Zink A, Listing J, Kary S et al (2005) Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis 64(9):1274\u20131279","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6916_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"ML Hetland","year":"2010","unstructured":"Hetland ML, Christensen IJ, Tarp U et al (2010) Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62(1):22\u201332","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6916_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1080\/10717544.2019.1587043","volume":"26","author":"BJF van den Bemt","year":"2019","unstructured":"van den Bemt BJF, Gettings L, Doma\u0144ska B et al (2019) A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Deliv 26(1):384\u2013392","journal-title":"Drug Deliv"},{"issue":"8","key":"6916_CR23","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/1756-185X.13243","volume":"21","author":"G Jones","year":"2018","unstructured":"Jones G, Hall S, Bird P et al (2018) A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. Int J Rheum Dis 21(8):1581\u20131590","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"6916_CR24","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324","journal-title":"Arthritis Rheum"},{"issue":"suppl 6","key":"6916_CR25","doi-asserted-by":"publisher","first-page":"vi5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS (2012) ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51(suppl 6):vi5\u2013vi9","journal-title":"Rheumatology"},{"issue":"5","key":"6916_CR26","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"J Anderson","year":"2012","unstructured":"Anderson J, Caplan L, Yazdany J et al (2012) Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 64(5):640\u2013647","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5 Suppl 39","key":"6916_CR27","first-page":"S93","volume":"23","author":"J Fransen","year":"2005","unstructured":"Fransen J, van Riel PL (2005) The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93\u2013S99","journal-title":"Clin Exp Rheumatol"},{"key":"6916_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcome 1:20","journal-title":"Health Qual Life Outcome"},{"issue":"5 Suppl 39","key":"6916_CR29","first-page":"S77","volume":"23","author":"T Sokka","year":"2005","unstructured":"Sokka T (2005) Assessment of pain in rheumatic diseases. Clin Exp Rheumatol 23(5 Suppl 39):S77-84","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 11","key":"6916_CR30","first-page":"S14","volume":"63","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L et al (2011) Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score with 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA). Arthritis Care Res (Hoboken) 63(Suppl 11):S14-36","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"6916_CR31","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/acr.20265","volume":"62","author":"J Anderson","year":"2010","unstructured":"Anderson J, Sayles H, Curtis JR et al (2010) Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 62(10):1481\u20131488","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"6916_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40744-020-00201-y","volume":"7","author":"JH Best","year":"2020","unstructured":"Best JH, Vlad SC, Tominna L et al (2020) Real-world persistence with tocilizumab compared to other subcutaneous biologic disease-modifying antirheumatic drugs among patients with rheumatoid arthritis switching from another biologic. Rheumatol Ther 7(2):345\u2013355","journal-title":"Rheumatol Ther"},{"issue":"7","key":"6916_CR33","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.clinthera.2011.06.001","volume":"33","author":"MA Blum","year":"2011","unstructured":"Blum MA, Koo D, Doshi JA (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33(7):901\u2013913","journal-title":"Clin Ther"},{"key":"6916_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.2147\/ppa.s303279","volume":"15","author":"PM Overton","year":"2021","unstructured":"Overton PM, Shalet N, Somers F et al (2021) Patient preferences for subcutaneous versus intravenous administration of treatment for chronic immune system disorders: a systematic review. Patient Prefer Adherence 15:811\u2013834. https:\/\/doi.org\/10.2147\/ppa.s303279","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"6916_CR35","doi-asserted-by":"publisher","first-page":"21090","DOI":"10.1038\/s41598-022-21533-5","volume":"12","author":"Y Sobue","year":"2022","unstructured":"Sobue Y, Suzuki M, Ohashi Y et al (2022) Validation of grip strength as a measure of frailty in rheumatoid arthritis. Sci Rep 12(1):21090","journal-title":"Sci Rep"},{"issue":"11","key":"6916_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s10916-021-01778-9","volume":"45","author":"F Salaffi","year":"2021","unstructured":"Salaffi F, Carotti M, Farah S et al (2021) Handgrip strength features in rheumatoid arthritis patients assessed using an innovative cylindrical-shaped device: relationships with demographic, anthropometric and clinical variables. J Med Syst 45(11):100","journal-title":"J Med Syst"},{"key":"6916_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/PPA.S5835","volume":"3","author":"JL Barton","year":"2009","unstructured":"Barton JL (2009) Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 3:335\u201344","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"6916_CR38","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kel369","volume":"45","author":"EL Williams","year":"2006","unstructured":"Williams EL, Edwards CJ (2006) Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford) 45(12):1575\u20131576","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6916_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA (2008) Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care 6(1):1\u201314","journal-title":"Musculoskeletal Care"},{"issue":"3","key":"6916_CR40","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40744-021-00325-9","volume":"8","author":"M Kishimoto","year":"2021","unstructured":"Kishimoto M, Yamairi F, Sato N et al (2021) Patient preference for treatment mode of biologics in rheumatoid arthritis: a 2020 web-based survey in Japan. Rheumatol Ther 8(3):1095\u20131111","journal-title":"Rheumatol Ther"},{"issue":"3","key":"6916_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/acr.22110","volume":"66","author":"A Ogata","year":"2014","unstructured":"Ogata A, Tanimura K, Sugimoto T et al (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66(3):344\u2013354","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"6916_CR42","doi-asserted-by":"publisher","first-page":"rkz010","DOI":"10.1093\/rap\/rkz010","volume":"3","author":"JD Isaacs","year":"2019","unstructured":"Isaacs JD, Salih A, Sheeran T et al (2019) Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatol Adv Pract 3(1):rkz010","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"6916_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/rheumatology\/kex443","volume":"57","author":"E Choy","year":"2018","unstructured":"Choy E, Caporali R, Xavier R et al (2018) Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology 57(3):499\u2013507","journal-title":"Rheumatology"},{"key":"6916_CR44","doi-asserted-by":"publisher","first-page":"e000809","DOI":"10.1136\/rmdopen-2018-000809","volume":"4","author":"K Lauper","year":"2018","unstructured":"Lauper K, Mongin D, Iannone F et al (2018) Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries. RMD open 4:e000809. https:\/\/doi.org\/10.1136\/rmdopen-2018-000809","journal-title":"RMD open"},{"key":"6916_CR45","first-page":"1189","volume":"76","author":"G Pomponio","year":"2017","unstructured":"Pomponio G, Tontini C, Angeletti A et al (2017) AB0400 Efficacy and safety of intravenous and subcutaneous tocilizumab in a cohort of patients affected by rheumatoid arthritis in real-life. Ann Rheum Dis 76:1189","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6916_CR46","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3899\/jrheum.120687","volume":"40","author":"MC Genovese","year":"2013","unstructured":"Genovese MC, Rubbert-Roth A, Smolen JS et al (2013) Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 40(6):768\u201380","journal-title":"J Rheumatol"},{"issue":"9990","key":"6916_CR47","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","volume":"386","author":"JA Singh","year":"2015","unstructured":"Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet 386(9990):258\u2013265","journal-title":"Lancet"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06916-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06916-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T06:03:32Z","timestamp":1713161012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06916-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["6916"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06916-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the participating sites\u2019 Scientific Committee prior to the initiation of any activities.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was acquired from all study participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written consent was acquired from all participants and authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"\u2022 Dr Athanasiou has received speaker honoraria from Roche.\u2022 Dr Katsimbri has received honoraria and advisory board fees from Genesis Pharma, UCB, AbbVie, Amgen Hellas, Aeonorasis, Actelion, Novartis, Janssen and Pfizer\u2022 Dr Bounas has received honoraria for lectures, presentations, manuscript writing and advisory board participation from Abbvie, Aeonorasis, Amgen, Bausch Health, FARAN, Genesis Pharma, GSK, Janssen, MSD, Novartis, Pfizer and UCB.\u2022 Dr Gazi has received travel support from Jannsen, Abbvie, Pfizer, Genesis Pharma and Vianex. Advisory board fees from Boehringer Ingelheim and consultancy fees from Amgen.\u2022 Dr Sarikoudis has received\u00a0travel support from Pfizer\u2022 Prof Boumpas has received honoraria for lectures, presentations and advisory board participation from Pfizer, Aeonorasis, \u0391strazeneca and GSK.\u2022 V. Syrigou, is an employee of Roche Hellas S.A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}